A Phase I Study of Intravenous LB-100 for Injection as a Single Agent and in Combination With Docetaxel in the Treatment of Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 04 Jan 2017
At a glance
- Drugs LB 100 (Primary) ; Docetaxel
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Lixte Biotechnology Holdings
- 04 Jan 2017 Results published in a Lixte Biotechnology Holdings media release.
- 04 Jan 2017 According to a Lixte Biotechnology Holdings media release, results published in Clinical Cancer Research.
- 28 Sep 2016 Status changed from active, no longer recruiting to completed.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History